Tadalafil Tablet, Film Coated
Product Images NDC 51655-063

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 51655-063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 063 54)

Label for Tadalafil Tablets, USP 20 mg, film-coated oral tablets, in a package of 15 tablets. The label indicates prescription use only, with storage instructions to keep at 20°-25°C (68°-77°F) and to store in the original container. Labeler is Northwind Health Company, LLC, with NDC 51655-063.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 01)

Chemical structure of Tadalafil, an active pharmaceutical ingredient used in human prescription drugs. The structure displays the characteristic fused ring system and functional groups typical of Tadalafil molecules.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 02)

A set of four line graphs showing the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours. The panels represent Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP. Each graph includes error bars indicating variability at each time point, with measurements spanning 0 to 96 hours.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 03)

A line graph depicting the effect on standing and supine systolic blood pressure (BP) over 24 hours post-dose. Two lines compare Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg, showing BP changes in mmHg on the y-axis and time in hours on the x-axis.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 04)

A line graph showing systolic blood pressure (mmHg) over time after administration of tadalafil or placebo. The graph compares four groups: 20 mg tadalafil at 08:00 with 8 mg qd doxazosin at 08:00, placebo at 08:00 with 8 mg qd doxazosin at 08:00, 20 mg tadalafil at 20:00 with 8 mg qd doxazosin at 08:00, and placebo at 20:00 with 8 mg qd doxazosin at 08:00. The x-axis represents time up to 12 hours post-administration.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 05)

A line graph depicting plasma tadalafil concentrations (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following five consecutive days. The y-axis shows concentration levels, and the x-axis shows time up to 120 hours, with error bars indicating variability for each data point.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 06)

A line graph depicting the change from baseline in IPSS Total Score over a 12-week treatment period. It compares two groups: one receiving Tadalafil 5 mg (solid line with circles) and a placebo group (dashed line with triangles). The graph shows a greater decrease in scores for the Tadalafil group, indicating improvement over time compared to placebo.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 07)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment for Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12), while the y-axis shows the change from baseline score. Tadalafil 5 mg is shown with a solid line and circles, and placebo with a dashed line and triangles, indicating greater score improvement with Tadalafil over time.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 08)

Line graph showing mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph plots least-squares treatment differences at weeks 4, 12, and 26 indicating statistically significant results with annotations for p-values less than 0.001 and 0.05.*

FDA Label Image

Tadalafil Tablets (Bf07616c 918b 40b7 8ffb 7c6a12cd64e5 09)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment for Tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows change in IPSS total score. The Tadalafil group shows a greater reduction in score over time compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.